Mylan CEO Heather Bresch speaks to BT's P.B. Jayakumar on how the generic pharma sector is consolidating globally and Mylan's role in leading the transition from the front. Mylan CEO Heather Bresch If Mylan CEO Heather Bresch manages to complete the $27.1 billion hostile takeover of Ireland-based rival Perrigo, it would perhaps be her most valued acquisition and help her position the $7.72 billion generic and specialty pharmaceuticals company as one of the top three global generic pharma players. But then, successfully thwarting a similar attempt by another rival, Teva Pharmaceuticals, to acquire Mylan for $40 billion barely two months ago on July 23, was no mean deed either. In fact, the 46-year-old has been making history ever since she joined Mylan as a clerk in 1992, steadily rising up the ranks to serve as the companys chief operating officer, chief integration officer and president, before taking over as the first ever woman chief executive of a global pharma majo...